Kumthekar Priya, Patel Vaibhav, Bridge Carly, Rademaker Alfred, Helenowski Irene, Mrugala Maciej M, Rockhill Jason K, Grimm Sean, Swanson Kristin R, Raizer Jeffrey
Departments of Neurology, Neurosurgery and Preventive Medicine, Northwestern University, Feinberg School of Medicine, USA.
Department of Neurosurgery, Mayo Clinic Scotsdale, USA.
Integr Cancer Sci Ther. 2017 Oct;4(5). doi: 10.15761/icst.1000255. Epub 2017 Oct 23.
Clinical behavior, treatment parameters, and prognostic factors are less well defined in older adults with low-grade gliomas (LGG). We conducted a two-institution retrospective review of older patients with LGG to better understand disease characteristics and prognosis in this population.
Northwestern University (NU) and The University of Washington (UW) clinical research databases were queried for patients ≥ 50 years of age with a diagnosis of WHO grade II glioma between January 1, 2000 and December 2012 (UW). Medical records were reviewed and data relevant to diagnosis, treatment and outcomes were collected. PFS and OS with respect to prognostic factors were calculated. Log-rank test and multivariate proportional hazards models were calculated for multiple tumor characteristics.
Thirty-five patients with a diagnosis of LGG (WHO grade II) were identified; 15 women and 20 men had a median age of 55 (range 50-78). Fourteen had astrocytomas, fourteen had oligodendrogliomas and seven had oligoastrocytomas. Eight patients had contrast enhancement on neuroimaging, 9 of 21 tested had 1p19q co-deletion and 5 of 14 tested had an IDH1 mutation. Five year PFS was 21% with median PFS of 17 months; 20 patients had died (5 year OS=43%, median OS=48 months). On univariate analysis There was a statistically significant improvement in OS for patients with mixed histology (p=0.001), no midline shift at diagnosis (p=0.002) and with IDH1 mutation (p=0.003).
LGG appear more aggressive in older patients. Treatment following surgical resection should be considered; ongoing studies may clarify the most appropriate treatments for this age group.
在老年低级别胶质瘤(LGG)患者中,临床行为、治疗参数和预后因素的定义尚不明确。我们对两家机构的老年LGG患者进行了回顾性研究,以更好地了解该人群的疾病特征和预后。
查询西北大学(NU)和华盛顿大学(UW)的临床研究数据库,筛选出2000年1月1日至2012年12月(UW)期间年龄≥50岁、诊断为世界卫生组织(WHO)II级胶质瘤的患者。回顾病历并收集与诊断、治疗和结局相关的数据。计算无进展生存期(PFS)和总生存期(OS)与预后因素的关系。对多种肿瘤特征进行对数秩检验和多变量比例风险模型分析。
共确定35例诊断为LGG(WHO II级)的患者;15名女性和20名男性,中位年龄为55岁(范围50 - 78岁)。14例为星形细胞瘤,14例为少突胶质细胞瘤,7例为少突星形细胞瘤。8例患者神经影像学检查有强化表现,21例检测患者中有9例存在1p19q共缺失,14例检测患者中有5例存在异柠檬酸脱氢酶1(IDH1)突变。5年PFS为21%,中位PFS为17个月;20例患者死亡(5年OS = 43%,中位OS = 48个月)。单因素分析显示,组织学混合型患者的OS有统计学显著改善(p = 0.001),诊断时无中线移位患者的OS有统计学显著改善(p = 0.002),存在IDH1突变患者的OS有统计学显著改善(p = 0.003)。
LGG在老年患者中似乎更具侵袭性。手术切除后应考虑进行治疗;正在进行的研究可能会明确该年龄组最合适的治疗方法。